{
    "eid": "2-s2.0-85165945752",
    "title": "Efficacy and safety of different dual antiplatelet strategies in patients undergoing percutaneous coronary intervention: A systematic review and network meta-analysis",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "de-escalation",
        "percutaneous coronary intervention",
        "short dual antiplatelet therapy"
    ],
    "authors": [
        "Yuttana Wongsalap",
        "Kirati Kengkla",
        "Preyanate Wilairat",
        "Khemanat Ratworawong",
        "Surasak Saokaew",
        "Chaisiri Wanlapakorn"
    ],
    "citedby-count": 0,
    "ref-count": 51,
    "ref-list": [
        "2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation",
        "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)",
        "2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease",
        "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)",
        "Ticagrelor versus clopidogrel in patients with acute coronary syndromes",
        "Prasugrel versus clopidogrel in patients with acute coronary syndromes",
        "Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey",
        "Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)",
        "Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial",
        "Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial",
        "A new strategy for discontinuation of dual antiplatelet therapy",
        "Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial",
        "Ticagrelor with or without Aspirin in high-risk patients after PCI",
        "Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial",
        "Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial",
        "Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials",
        "Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials",
        "De-escalation of antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials",
        "Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes",
        "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews",
        "RoB 2: a revised tool for assessing risk of bias in randomised trials",
        "The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings",
        "Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium",
        "Meta-analysis in clinical trials",
        "Graphical tools for network meta-analysis in STATA",
        "Network meta-analysis",
        "Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies",
        "Evaluation of inconsistency in networks of interventions",
        "Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial",
        "A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI",
        "Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study",
        "Pharmacodynamic profile and prevalence of bleeding episode in east asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial",
        "Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial",
        "Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial",
        "Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial",
        "Bleeding events and maintenance dose of prasugrel: BLESS pilot study",
        "Pharmacodynamics and outcomes of a de-escalation strategy with half-dose prasugrel or ticagrelor in east asians patients with acute coronary syndrome: results from HOPE-TAILOR trial",
        "1-month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation",
        "Management of antithrombotic therapy after acute coronary syndromes",
        "Characterization of the average daily ischemic and bleeding risk after primary PCI for STEMI",
        "De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies",
        "One-month dual antiplatelet therapy following percutaneous coronary intervention with zotarolimus-eluting stents in high-bleeding-risk patients",
        "3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation",
        "Polymer-based or polymer-free stents in patients at high bleeding risk",
        "Meta-analysis of outcomes after intravascular ultrasound-guided versus angiography-guided drug-eluting stent implantation in 26,503 patients enrolled in three randomized trials and 14 observational studies",
        "Effect of intravascular ultrasound\u2013guided drug-eluting stent implantation",
        "Use of IVUS guided coronary stenting with drug eluting stent",
        "Polymer-free drug-coated coronary stents in patients with stable coronary artery disease at high bleeding risk",
        "Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients",
        "Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Phayao",
            "@id": "60114221",
            "affilname": "University of Phayao",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60114221",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "University of Phayao",
        "Thailand Science Research and Innovation fund"
    ]
}